Page 115 - Cap Ltd News Today

    K3 Capital Group plc, a multi-disciplinary professional services firm providing advisory services to SMEs, today announces its interim results for the six months ended 30 November 2020.     · Group revenue £17.8m (H1 2020: £8.0m), with first-time contribution from acquisitions randd and Quantuma (limited to 4 months of trading) · All group companies trading strongly despite COVID impact and national lockdowns: o...

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any natio...

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any natio...

Pages 95 to 130 7.2  Grant Thornton UK LLP of 30 Finsbury Square, London EC2A 1AG are the current auditors of the Company. Deloitte LLP of 1 New Street Square, London EC4A 3HQ were the auditors for the Company up to the financial period to 30 March 2019. 8.  dividend policy 8.1  The Boards dividend policy was most recently stated on page 6 in the Chairmans Statement contained in the 2020 Annual Report & Accounts which forms part of the Companys Public Record: "The Company has not paid a ...

Highlights · Raising up to £2million via £1.5million Placing and £500,000 Broker Option primarily to fund multiple work programmes focused on: o Evaluating late-stage appraisal/development projects that would rebalance existing portfolio of production and exploration assets o Improving recovery from existing onshore UK fields including potential workovers on WF2 and WF9 wells at the West Firsby field o Continuing technical analysis a...

Investegate announcements from Omega Diagnostics Gp, UK Government contract and trading update

    Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance testing, announces the appointment of Dr Simon Douglas as independent Non-Executive Chairman. Simon has been appointed to the Board with immediate effect, after a thorough search process that was conducted with the help of Snedden Campbell Ltd. Simon has also become a member of both the Audit Committee and the Remuneration Committee.   Simon has 25 year...

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any natio...

About IOG:   IOG owns and operates a 50% stake in substantial low risk, high value gas reserves in the UK Southern North Sea. The Companys Core Project targets a gross 2P peak production rate of 140 MMcfe/d (c. 24,000 Boe/d) from gross 2P gas Reserves of 302 Bcfe¹ + 2C gas Contingent Resources of 108 Bcfe², via an efficient hub strategy. In addition to the independently verified 2P reserves at Blythe, Elgood, Southwark, Nailsworth and Elland and 2C Contingent Resources at G...

ANGLE plc: Angle Plc - Announces Parsortix: Dynamic Assessment of Patient Response Use of Parsortix System Enables a Dynamic Assessment of Patient Response to Treatment in Non-Small Cell Lung Cancer CTCs harvested by the Parsortix system successfully used to measure the dynamic role of EMT and PD-L1 in patient response to therapy Findings support ANGLEs plan for the growth of a new "pharma services" business area using the Parsortix system as a biomarker for cancer drug trials allowing longitu...